Singapore-based digital therapeutics startup Respiree announces incorporation in U.S. with residency at JLABS, San Francisco

Singapore-based digital therapeutics startup Respiree announces incorporation in U.S. with residency at JLABS, San Francisco

Published: 15-04-2024 15:04:00 | By: Pie Kamau | hits: 1096 | Tags:

Singapore-based digital therapeutics startup Respiree, announced it has incorporated in the U.S. and will be incubating within Johnson & Johnson Innovation – JLABS @South San Francisco. By expanding footprint within the U.S., Respiree aims to deepen its relationships and networks within the pharma and life science sector. 

With a physical presence to the U.S., the Respiree team will focus on utilizing the iRIS One decentralized clinical trials platform to help pharma companies in the U.S. and broader global economies to optimize drug trials, discover newer lung and cardiac digital biomarkers and to aggregate broader and deeper real-world datasets. Respiree's team also aims to extend the development of its novel digital therapeutics pipeline to incorporate real-world pharma evidence.

Gurpreet Singh, Founder and CEO, Respiree: "We are very proud and excited to be continuing our JLABS journey, first as alumni of JLABS @ Shanghai, then JLABS Singapore and now to JLABS @ South San Francisco. We hope to work more closely within the life science and the pharmaceutical sector to enhance the iRIS One clinical trials platform. With our physical presence in the U.S., we hope to position ourselves to accelerate the development of our digital therapeutics pipeline with the ultimate aim of enabling patients to access better treatments faster."

Respiree received the 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration (FDA) on 8 March 2023. It has signed several commercial agreements with multi-national companies to assist in their go-to-market penetration.

www.respiree.com